Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (SRPT) announced 25 recipients of its Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year.
The academic scholarships include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne, each eligible for up to $5,000. Now in its ninth year, the program has awarded more than 150 scholarships to support postsecondary education. Recipients are selected by an independent committee of Duchenne community members based on academic record, community involvement, personal essay and recommendation letter, with applications de-identified regarding past or planned Sarepta therapies.
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live and available in the investor relations section of Sarepta’s website, where it will be archived for 90 days.
Sarepta Therapeutics (NASDAQ:SRPT) reported second quarter 2026 total revenues of $401.3 million, down 34% year over year, with net product revenues of $328.7 million (including $230.6 million PMO and $98.1 million ELEVIDYS). Q2 2026 GAAP operating income was $13.3 million and non-GAAP operating income was $86.5 million, while GAAP net loss was $4.9 million.
The company appointed Michael Severino, MD, as CEO effective July 28, 2026, and ended the quarter with $945.0 million in cash, cash equivalents, restricted cash and investments. Sarepta narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and non-GAAP R&D plus SG&A to $800.0-$850.0 million. Key pipeline updates include on-track Phase 1/2 MAD readouts in DM1 and FSHD in 2H 2026, dosing underway in the Phase 1 INSIGHTT study for Huntington’s disease candidate SRP-1005, and FDA acceptance of sNDAs to convert AMONDYS 45 and VYONDYS 53 to traditional approval.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards on July 28, 2026 to newly appointed CEO Michael Severino, M.D. under its 2024 Employment Commencement Incentive Plan, as a material inducement to employment and in accordance with Nasdaq Listing Rule 5635(c)(4).
According to Sarepta, Dr. Severino received options to purchase 2,224,342 shares of common stock at an exercise price of $17.74 per share, set at a 15% premium to the Grant Date closing price, plus 756,104 restricted stock units. The options vest over four years with a one-year cliff, and the RSUs vest annually over four years, in each case generally subject to his continued employment.
Sarepta Therapeutics (NASDAQ: SRPT) appointed Michael Severino, M.D. as chief executive officer, effective July 28, 2026, and to its Board of Directors. He succeeds Doug Ingram, who is retiring and will remain in an advisory role through the end of 2026 to support transition.
According to Sarepta, Severino brings more than 25 years of biopharmaceutical leadership, including roles as CEO of Tessera Therapeutics and Vice Chairman and President at AbbVie, where he oversaw R&D, corporate strategy and expansion of precision medicine capabilities. The company highlights its leadership in Duchenne muscular dystrophy and a portfolio spanning muscle, CNS and cardiac rare diseases.
Sarepta Therapeutics (NASDAQ:SRPT) will report its second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2026. The company will host a conference call at 4:30 p.m. ET, with a live webcast and one-year replay available in the investor relations section of its website.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards on June 30, 2026 under its 2024 Employment Commencement Incentive Plan as material inducements for 30 second-quarter hires. The awards total 151,305 restricted stock units (RSUs), approved in accordance with Nasdaq Listing Rule 5635(c)(4).
RSUs vest over four years, with one-fourth vesting annually on each grant-date anniversary, subject to continued employment. No stock options were granted.
Sarepta Therapeutics (NASDAQ:SRPT) announced that the FDA has accepted for review supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 to convert their accelerated approvals in Duchenne muscular dystrophy to traditional approvals. The FDA set a PDUFA target action date of February 28, 2027.
The filings are supported by Phase 3 ESSENCE data, extensive real-world evidence in over 1,800 treated patients, and established safety profiles. In ESSENCE, the primary endpoint was not met, though numerical trends favored treatment and week‑96 data showed increased dystrophin and functional preservation.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in two June 2026 investor events in Miami Beach. Senior management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 and hold investor meetings at the Oppenheimer CNS and Neuro-Muscular Summit on June 10.
The Goldman Sachs fireside chat will be webcast live and archived for 90 days in the investor relations section of Sarepta’s website. Sarepta highlights its focus on precision genetic medicine for rare diseases and encourages investors to check the “For Investors” section of its website for updates.
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will take part in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET.
The presentation will be webcast live and archived for 90 days on Sarepta’s investor relations website.